Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone palmitate + ropivacaine thoracic paravertebral injection for thoracic herpes zoster pain
ChiCTR2400087273Phase 2Not yet recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dexamethasone, ropivacaine and famciclovir in herpes zoster (HZ) (2 arms), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoint: Incidence rate of postherpetic neuralgia at Month 12. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
dexamethasoneropivacainefamciclovir
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on ChiCTR2400087273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087273.